Poolbeg Pharma PLC (LON:POLB – Get Free Report)’s stock price traded down 19% during mid-day trading on Friday . The stock traded as low as GBX 3.70 ($0.05) and last traded at GBX 3.89 ($0.05). 3,471,574 shares were traded during trading, an increase of 0% from the average session volume of 3,471,285 shares. The stock had previously closed at GBX 4.80 ($0.06).
Analysts Set New Price Targets
Separately, Shore Capital restated a “house stock” rating on shares of Poolbeg Pharma in a research report on Thursday, January 2nd.
View Our Latest Stock Report on POLB
Poolbeg Pharma Stock Down 17.7 %
About Poolbeg Pharma
Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.
See Also
- Five stocks we like better than Poolbeg Pharma
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- Breakout Stocks: What They Are and How to Identify Them
- DuPont’s Electronics Spinoff: The Start of Something Big
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
